Differential cell responses to nanoparticle docetaxel and small molecule docetaxel at a sub-therapeutic dose range

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 2, 2014, Pages 321-328

  Wang, Edina C ^a,b   Sinnott, Rebecca ^a   Werner, Michael E ^a,b   Sethi, Manish ^a,b   Whitehurst, Angelique W ^a   Wang, Andrew Z ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Controlled drug release; Cytotoxicity; Drug delivery; Nanomedicine; Nanoparticle

Indexed keywords

CELLULAR EFFECTS; CELLULAR RESPONSE; CONTROLLED DRUG RELEASE; DIFFERENTIAL EFFECT; NANOPARTICLE FORMULATION; NANOPARTICLE SIZES; POLYMERIC NANOPARTICLES; THERAPEUTIC EFFECTS;

CELLS; CYTOTOXICITY; DRUG DELIVERY; DRUG PRODUCTS; MEDICAL NANOTECHNOLOGY; MOLECULES; NANOPARTICLES;

CYTOLOGY;

DOCETAXEL; NANOPARTICLE;

ARTICLE; CELL CYCLE; CELL FATE; CELL FUNCTION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; THERAPY EFFECT;

CONTROLLED DRUG RELEASE; CYTOTOXICITY; DRUG DELIVERY; NANOMEDICINE; NANOPARTICLE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FIBROBLASTS; GREEN FLUORESCENT PROTEINS; HUMANS; MICELLES; NANOMEDICINE; NANOPARTICLES; PARTICLE SIZE; POLYMERS; TAXOIDS;

EID: 84893352321     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.07.012     Document Type: Article

References (30)

1. Rowinsky M., Eric K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med 1997, 48:353-374.
2. Goldspiel B.R. Clinical overview of the taxanes. Pharmacotherapy 1997, 17:110S-125S.
3. Adams J.D., Flora K.P., Goldspiel B.R., Wilson J.W., Arbuck S.G., Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst 1993, 15:141-147.
4. Rowinsky E.K., Eisenhauer E.A., Chaudhry V., Arbuck S.G., Donehower R.C. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993, 20:1-15.
5. Engels F.K., Mathot R.A.A., Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs 2007, 18:95-103.
6. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005, 5:161-171.
7. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
8. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
9. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012, 63:185-198.
10. Hrkach J., Von Hoff D., Ali M.M., et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med 2012, 4:128ra39.
11. Lee K., Chung H., Im S., et al. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008, 108:241-250.
12. Gradishar W.J., Tjulandin S., Davidson N., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005, 23:7794-7803.
13. Chithrani B.D., Ghazani A.A., Chan W.C.W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett 2006, 6:662-668.
14. Rejman J., Oberle V., Zuhorn I.S., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169.
15. Burda C., Chen X., Narayanan R., El-Sayed M.A. Chemistry and properties of nanocrystals of different shapes. Chem Rev 2005, 105:1025-1102.
16. Huang X., Teng X., Chen D., Tang F., He J. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 2010, 31:438-448.
17. Abal M., Andreu J.M., Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003, 3:193-203.
18. Huizing M.T., Misser V.H.S., Pieters R.C., et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995, 13:381-404.
19. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004, 4:253-265.
20. Blagosklonny M.V. Mitotic arrest and cell fate: why and how mitotic inhibition of transcription drives mutually exclusive events. Cell Cycle 2007, 6:70-74.
21. Blajeski A.L., Kottke T.J., Kaufmann S.H. A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res 2001, 270:277-288.
22. Gascoigne K.E., Taylor S.S. How do anti-mitotic drugs kill cancer cells?. J Cell Sci 2009, 122:2579-2585.
23. Torres K., Horwitz S.B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998, 58:3620-3626.
24. Pridgen E.M., Langer R., Farokhzad O.C. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine 2007, 2:669-680.
25. Jung K.H., Kim K.-P., Yoon D.H., et al. A phase I trial to determine the maximum tolerated dose and evaluate the safety and pharmacokinetics (PK) of docetaxel-PNP, polymeric nanoparticle formulation of docetaxel, in subjects with advanced solid malignancies. ASCO Meeting Abstracts. 2012, 30:e13104.
26. Zhang L., Chan J.M., Gu F.X., et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2008, 2:1696-1702.
27. Werner M.E., Copp J.A., Karve S., et al. Folate-targeted polymeric nanoparticle formulation of docetaxel is an effective molecularly targeted radiosensitizer with efficacy dependent on the timing of radiotherapy. ACS Nano 2011, 5:8990-8998.
28. Kamaly N., Xiao Z., Valencia P.M., Radovic-Moreno A.F., Farokhzad O.C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012, 41:2971-3010.
29. Ikui A.E., Yang C.-P.H., Matsumoto T., Horwitz S.B. Low concentrations of taxol cause mitotic delay followed by premature dissociation of p55CDC from Mad2 and BubR1 and abrogation of the spindle checkpoint, leading to aneuploidy. Cell Cycle. 2005, 4:1385-1388.
30. Demidenko Z.N., Kalurupalle S., Hanko C., Lim Cu., Broude E., Blagosklonny M.V. Mechanism of G1-like arrest by low concentrations of paclitaxel: next cell cycle p53-dependent arrest with sub G1 DNA content mediated by prolonged mitosis. Oncogene 2008, 27:4402-4410.